Lead molecule in the clinic and a pipeline for the future

QBiotics has identified significant unmet medical needs and market opportunities in a range of therapeutic areas.

Our current focus is on treating solid tumours and chronic wounds

Our lead molecule,  tigilanol tiglate, is a small molecule that destroys a range of solid tumours across multiple species with a single injection.

While our initial focus for the human market is head and neck cancer, melanoma and soft tissue sarcoma, tigilanol tiglate has “tumour agnostic” activity and therefore, has the potential to treat other difficult-to-treat solid tumours.

Our second lead molecule EBC-1013  is being developed for a spectrum of difficult-to-treat chronic and acute wounds and burns.